Analyst Research

Report Title Price
Provider: Reuters Investment Profile
$20.00
Provider: ValuEngine, Inc.
$25.00
Provider: Wright Reports
$75.00
Provider: Thomson Reuters StreetEvents
$75.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Genmab A/S Maintains FY 2013 Guidance-Ritzau


Wednesday, 6 Nov 2013 11:14am EST 

Ritzau reported that Genmab A/S has decided to maintain its guidance for the fiscal year 2013. The Company expects to report revenue of between DKK 550 million and DKK 590 million, and a negative operating profit of between DKK 10 million and DKK 75 million for the fiscal year 2013. 

Company Quote

237.8
4.0 +1.71%
19 Sep 2014